Saltz L - Search Results

1

Evolving treatment of advanced colorectal cancer.

Cercek A, Saltz L. Cercek A, et al. Among authors: saltz l. Curr Oncol Rep. 2010 May;12(3):153-9. doi: 10.1007/s11912-010-0096-1. Epub 2010 Mar 27. Curr Oncol Rep. 2010. PMID: 20425074 Review.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.

Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. Saltz LB, et al. Cancer. 1995 Feb 1;75(3):782-5. doi: 10.1002/1097-0142(19950201)75:3<782::aid-cncr2820750306>3.0.co;2-i. Cancer. 1995. PMID: 7828128 Clinical Trial.

4

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

5

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

6

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

7

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

8

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.

Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. Saltz LB, et al. Am J Clin Oncol. 1997 Dec;20(6):621-5. doi: 10.1097/00000421-199712000-00018. Am J Clin Oncol. 1997. PMID: 9391553 Clinical Trial.

9

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

10

Irinotecan and cisplatin in upper gastrointestinal malignancies.

Enzinger PC, Ilson DH, Saltz LB, O'Reilly EM, Kelsen DP. Enzinger PC, et al. Among authors: saltz lb. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):110-3. Oncology (Williston Park). 1998. PMID: 9726102 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

511 results

Search Page

Filters